Wide Ranks

CPRX

Catalyst Pharmaceuticals, Inc.

22.34

Top Statistics
Market Cap 2 B Forward PE 10.67 Revenue Growth 25.30 %
Current Ratio 5.11 Trailing PE 18.93 Earnings Growth 0.00 %
Profit Margins 31.01 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 10.53 Enterprise / Revenue 4.83 Price To Sales Trailing12 Months 5.79
Profitability
Profit Margins 31.01 % Operating Margins 39.56 %
Balance Sheet
Total Cash 442 M Total Cash Per Share 3.71 Total Debt 3 M
Total Debt To Equity 0.4970 Current Ratio 5.11 Book Value Per Share 5.54
All Measures
Short Ratio 566.00 % Message Board Id finmb_5103575 Shares Short Prior Month 5 M
Return On Equity 0.2829 City Coral Gables Uuid 701918ca-1fbf-3631-8a48-a246327450bb
Previous Close 21.93 First Trade Date Epoch Utc 1 B Book Value 5.54
Beta 0.7550 Total Debt 3 M Volume 1 M
Price To Book 4.03 Fifty Two Week Low 13.00 Total Cash Per Share 3.71
Total Revenue 460 M Shares Short Previous Month Date 1 B Target Median Price 31.00
Audit Risk 8 Max Age 86400 Recommendation Mean 1.25
Sand P52 Week Change 0.3133 Operating Margins 39.56 % Target Mean Price 32.25
Net Income To Common 142 M Short Percent Of Float 0.0591 Implied Shares Outstanding 119 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M
Average Volume10days 1 M Total Cash 442 M Next Fiscal Year End 1 B
Revenue Per Share 4.00 Held Percent Insiders 0.0598 Ebitda Margins 45.92 %
Trailing PE 18.93 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 3 Regular Market Previous Close 21.93 Target Low Price 28.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 21.21 Open 22.00
Free Cashflow 150 M State FL Dividend Yield 0.00 %
Return On Assets 0.1835 Time Zone Short Name EST Board Risk 6
Trailing Eps 1.18 Day Low 21.63 Address1 355 Alhambra Circle
Shares Outstanding 119 M Compensation Risk 7 Price Hint 2
Target High Price 38.00 Website https://www.catalystpharma.com 52 Week Change 0.5482
Average Volume 964617 Forward Eps 1.51 Recommendation Key strong_buy
Compensation As Of Epoch Date 1 B Quick Ratio 475.00 % Is_sp_500 False
Regular Market Day High 23.01 Profit Margins 31.01 % Debt To Equity 0.4970
Fifty Two Week High 24.27 Day High 23.01 Shares Short 5 M
Regular Market Open 22.00 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 4.83 Revenue Growth 25.30 % Shares Percent Shares Out 0.0476
Operating Cashflow 224 M Currency USD Time Zone Full Name America/New_York
Market Cap 2 B Is_nasdaq_100 False Zip 33134
Quote Type EQUITY Industry Biotechnology Long Name Catalyst Pharmaceuticals, Inc.
Overall Risk 5 Regular Market Day Low 21.63 Held Percent Institutions 0.8185
Current Price 22.34 Address2 Suite 801 Enterprise To Ebitda 10.53
Financial Currency USD Current Ratio 5.11 Gross Margins 83.97 %
Industry Disp Biotechnology Number Of Analyst Opinions 8 Country United States
Float Shares 103 M Two Hundred Day Average 17.73 Governance Epoch Date 1 B
Enterprise Value 2 B Price To Sales Trailing12 Months 5.79 Forward PE 10.67
Regular Market Volume 1 M Ebitda 211 M Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.

It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type.

It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets.

The company was founded in 2002 and is based in Coral Gables, Florida.